Participated · Equity · May 2021

Caris Life Sciences is a next-generation AI TechBio company and precision medicine pioneer that provides comprehensive molecular profiling through Whole Exome and Whole Transcriptome Sequencing. The company launched MI Cancer Seek after receiving FDA approval; it is the first and only simultaneous WES/WTS-based assay with FDA-approved CDx indications for molecular profiling of solid tumors in adult and pediatric patients. In 2024 Caris commercially launched Caris Assure, a minimally invasive, blood-based assay using a circulating Nucleic Acid Sequencing (cNAS) approach to analyze cell-free DNA and RNA as well as genomic DNA and mRNA from white blood cells to distinguish somatic tumor, incidental clonal hematopoiesis and incidental germline variants. Caris combines sequencing power, big data and AI/machine learning to build a large-scale, multimodal database and computing capability to analyze the molecular complexity of disease. The company says it will use its platform to deliver next-generation precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development and to bring its science and technologies to more patients. Financially, Caris closed a $168 million growth capital round and has raised $1.86 billion in capital since 2018. Caris Life Sciences develops comprehensive molecular profiling that analyzes DNA (whole exome sequencing), RNA (whole transcriptome sequencing), and protein biomarkers to reveal a patient’s molecular blueprint for selecting therapies. The company applies sophisticated AI and machine learning to identify proprietary signatures that classify cancer at the molecular level and predict patient response. Caris maintains a molecular database of over 455,000 tumor profiles, including more than 350,000 profiles with matched molecular data and clinical outcomes. Founded in 2008, the company positions itself as a leading innovator in precision medicine. Caris plans to use new capital to repay outstanding debt, enhance its precision medicine platform, and for general corporate purposes. Since 2018 the company has raised approximately $1.7 billion in capital. Caris Life Sciences provides molecular profiling services that assess DNA, RNA and proteins to create a molecular blueprint that supports personalized cancer treatment decisions. The company combines its service offering, Caris Molecular Intelligence®, with its proprietary AI analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. Caris couples these molecular data with mature clinical outcomes on thousands of patients to generate insights for patients, physicians, payers and biopharmaceutical organizations. The company is headquartered in Irving, Texas and has offices in Phoenix, Denver, New York and Basel, Switzerland, providing services across the U.S., Europe, Asia and other international markets. David D. Halbert leads the company as Chairman and CEO. The business emphasizes integrating molecular science and artificial intelligence to advance precision medicine. Caris Life Sciences develops molecular profiling and analytics to guide precision oncology decisions, offering whole exome and whole transcriptome sequencing and proteome analysis. Its product suite includes MI Exome™ and MI Transcriptome™ sequencing, Caris MAI™ (Molecular Artificial Intelligence) and the DEAN™ analytics engine. Caris Pharmatech provides Just-In-Time clinical trial solutions and a network of over 200 research-ready oncology sites to speed site activation and patient enrollment. Headquartered in Irving, Texas, the company also has offices in Phoenix, Denver, New York and Basel and serves markets in the U.S., Europe, Asia and other international regions. The company will use new capital to fund continued growth in precision medicine, accelerate product development and pursue initiatives in the clinical trial and biopharmaceutical markets. Caris is led by Chairman and CEO David D. Halbert. Caris Life Sciences is an Irving, Texas-based provider of molecular science focused on precision medicine through molecular profiling of DNA, RNA and proteins. The company advances a suite of offerings including Caris Molecular Intelligence®, the ADAPT Biotargeting System™, and the DEAN™ AI analytics engine that together support its Next Generation Profiling™. Next Generation Profiling™ aims to analyze the whole exome, whole transcriptome and complete cancer proteome and couple that molecular data with mature clinical outcomes to deliver more precise treatment recommendations. Caris offers services throughout the U.S., Europe, Asia and other international markets. Led by Chairman and CEO David D. Halbert, the company plans to continue development of Next Generation Profiling™ and expand commercial, clinical and R&D laboratory capacity. In January 2018 it raised $150M in funding provided as senior secured debt and convertible notes to support development and other strategic initiatives.

Participated · Series E · Jun 2018

SigFig is a San Francisco-based investment advice service that uses data science and technology to provide guidance to investors across wealth levels. Founded in 2007 and led by CEO Mike Sha, the company offers consumer services via SigFig.com and an Enterprise Digital Wealth Management platform that powers automated investment services for institutions such as Wells Fargo, UBS and Citizens Bank. SigFig’s platform combines data science and technology to deliver the information and guidance investors need to achieve financial goals. The company raised $50M in a Series E funding round and intends to use the proceeds to accelerate investments in technology. The round included both strategic and institutional participants and resulted in a board appointment tied to the lead investor. SigFig develops tech-enabled financial advisory services and a direct asset management platform that includes CRM, client tools, and money management. The company positions itself as a full-service provider to financial services firms rather than an algorithmic robo-advisor like Wealthfront or Betterment. Its primary go-to-market is partnering with large banks and wealth managers to deploy customer-facing tools and engineer better client experiences. Through its direct asset management platform SigFig manages about $100 million, and the company says revenue is calculated based on assets under management. SigFig is pursuing deeper collaborations with major banks — notably a close partnership with UBS to work directly with wealth management advisors — as its growth strategy. CEO Michael Sha frames these institutional partnerships as the best way to get tech-based advisory tools into the hands of end investors. SigFig is a San Francisco-based financial services company that provides a service for people to manage and improve their investments by linking 410(k), IRA, trading, and advisor-managed accounts. The platform gives users a real-time view of their investments and recommends ways to adjust portfolios. Features include a real-time portfolio tracker plus charts and analytics. The company says it will use the $15M funding to continue to scale and improve SigFig and is hiring. SigFig is co-founded by CEO Mike Sha and President Parker Conrad and currently employs 40 people.